KIN1148 is a potent and selective small molecule inhibitor primarily investigated for its role in modulating cellular signaling pathways involved in cancer progression. It targets specific kinases implicated in tumor growth and survival, making it a valuable tool in oncology research. Its application lies in the development of targeted cancer therapies, particularly in tumors driven by dysregulated kinase activity. Researchers use KIN1148 to study pathway inhibition, apoptosis induction, and suppression of cell proliferation in preclinical models. Due to its selectivity, it helps minimize off-target effects, supporting its potential as a candidate for personalized medicine approaches. Additionally, KIN1148 is utilized in combination studies with other anticancer agents to evaluate synergistic effects and overcome drug resistance.